



BSET

British Society of
Endovascular Therapy

2022

ANNUAL MEETING



23rd – 24th June 2022 • Tortworth Court Hotel, South Gloucestershire

Our Sponsors

SOCIETY SPONSORS



GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS





BSET

British Society of
Endovascular Therapy

Annual Meeting 2022

Thursday 23rd June - Friday 24th June
Tortworth Court Hotel, South Gloucestershire

PROGRAMME

Thursday 23rd June	5
Friday 24th June	11

ABSTRACT SESSIONS

Session 1.....	16
Session 2.....	22
Aortic Prize Session	27
Session 3.....	33
Peripheral Prize Session	38
Posters.....	44
Our Sponsors.....	45
BSET Council	49



EXPECT DURABILITY

Designed to help you deliver a durable repair.

From the proximal to the distal seal, the Zenith Alpha™ Abdominal device is engineered to help you deliver a durable repair.

≥15 MM
PROXIMAL
SEAL ZONE

3 -PIECE
MODULAR
SYSTEM

DURABLE
REPAIR

Zenith Alpha®

ABDOMINAL ENDOVASCULAR GRAFT

EXPECT MORE.

Learn more at

cookmedical.eu/aortic-intervention or contact your local Cook Medical representative or Customer Service for details.

The Zenith Alpha® Endovascular System consists of:
Zenith Alpha Abdominal Endovascular Graft
Zenith Alpha Spiral-Z® Endovascular Leg

The image above also includes:

Zenith® Branch Endovascular Graft - Iliac Bifurcation

Please see product risk information in the IFU at cookmedical.eu



COOK®
MEDICAL

Thursday 23rd June

09.00 – 09.05	WELCOME <i>Colin Bicknell, BSET President</i>
09.05 – 9.40	ROULEAUX CLUB SYMPOSIUM
	<i>Chairs: Colin Bicknell, BSET President & Tamer El-Sayed, Rouleaux Club</i>
	The impact of COVID-19 on vascular training in the USA
	<i>Andres Schanzer, Chief, Division of Vascular Surgery, UMASS Memorial Health, USA</i>
	The impact of COVID on vascular training in the UK
	<i>James Rammell, Rouleaux Club</i>
09.40 – 09.50	The new vascular surgery curriculum and endovascular training in UK
	<i>Enrico Mancuso, Rouleaux Club</i>
	BSET FELLOWSHIP REPORT
	<i>Chairs: Patrick Chong & Paul Bevis</i>
09.50 – 10.30	2021 Training Fellowship
	<i>Badri Vijaynagar</i>
	2018 Travel Fellowship
	<i>Mehtab Ahmad</i>
09.50 – 10.30	ABSTRACT SESSION 1 (4+2 minutes) <i>Chairs: Patrick Chong & Paul Bevis</i>
09.50 – 09.56	Association of hospital volume with perioperative mortality of endovascular repair of complex aortic aneurysms – a nationwide cohort study Jorg Lucas de Bruin¹ , Anna Alberga ^{1,2} , Henc Verhagen ¹ ¹ Erasmus Medical Center, Rotterdam, Netherlands ² DICA, Leiden, Netherlands
09.56 – 10.02	Mortality associated with delayed vascular surgery during the Covid-19 pandemic disproportionately affects female patients Ethan Moore¹ , Max Wohlaue ¹ , Mahmood Kabeil ¹ , Riley Gillette ¹ , Nicolas Mouawad ² , Jason Chuen ³ , Joseph Mills ⁴ , Judith Lin ⁵ , London Guidry Lyons ⁶ , Issam Koleilat ⁷ , Leigh Ann O'Banion ⁸ , Robert Cuff ⁹ ¹ University of Colorado Anschutz Medical Campus, Aurora, USA ² McLaren Health System, Bay City, USA ³ Austin Health, Heidelberg, Australia ⁴ Baylor College of Medicine, Houston, USA ⁵ Michigan State University, East Lansing, USA ⁶ Louisiana State University Program, New Orleans, USA ⁷ RWJBarnabas Health, Toms River, USA ⁸ University of California San Francisco (UCSF) Fresno, Fresno, USA ⁹ Spectrum Health, Grand Rapids, USA

Thursday 23rd June

10.02 – 10.08	Social deprivation and the association with survival following Fenestrated Endovascular Aneurysm Repair <i>Ehsanul Choudhury, James Rammell, Nikesh Dattani, James McCaslin, James Prentis, Sandip Nandhra</i> Northern Vascular Centre, Newcastle
10.08 – 10.14	Initial UK experience using a dedicated venous mechanical thrombectomy device in patients presenting with acute deep vein thrombosis Chiragh Shah, Emma Wilton, Andrew Wigham Thames Valley Vascular Network, Oxford
10.14 – 10.20	Small abdominal aortic aneurysms in the over 85s ... Do we need to survey them? Sally Maryosh, Brenig Gwilym, Danielle Lowry, Madlen Dewi, Peter Lewis, David McLain, David Lewis, David Bosanquet Department of Vascular Surgery, Aneurin Bevan Health Board Hospitals, Wales
10.20 – 10.26	EVAR in octogenarians is safe: A meta-analysis and meta-regression Charles Hallett¹, Yousef Yousef², Kunal Namjoshi¹, Nina Al-Saadi², Isabel O'Shea³, Robert Hicks², David Sidloff⁴ ¹University Hospitals of Leicester, Leicester ²Northampton General Hospital, Northampton ³North Middlesex University Hospital, London ⁴Queen's Medical Centre, Nottingham
10.30 – 10.50	GUEST LECTURE (15+5 minutes) <i>Chairs: Chris Twine & Paul Moxey</i> Deep venous arterialisation for patients with critical limb threatening ischaemia <i>Daniela Branzan, Head of Vascular Surgery, University Medicine Leipzig</i>
10.50 – 11.20	COFFEE
11.20 – 11.40	SOCIETY SPONSOR: COOK MEDICAL <i>Chairs: Bijan Modarai & Nikos Tsilimparis</i> Commercial headwinds <i>Declan Dunphy, Commercial Business Manager, EMEA, Cook Medical</i>
11.40 – 12.00	GUEST LECTURE (15+5 minutes) <i>Chairs: Bijan Modarai & Nikos Tsilimparis</i> How the aortic research consortium is advancing complex endovascular treatment of aortic disease by providing next generation evidence <i>Andres Schanzer, Chief, Division of Vascular Surgery, UMASS Memorial Health, USA</i>

Thursday 23rd June

12.00 – 12.20	SOCIETY SPONSOR: GORE MEDICAL	
	<i>Chairs: James McCaslin & Simon Neequaye & Nuno Dias</i>	
	The Treatment of Aortoiliac Disease: Clinical Data and Best Practices with the Gore Viabahn VBX Balloon Expandable Endoprosthesis	
	<i>Martin Claridge, Consultant Vascular Surgeon, Birmingham</i>	
12.20 – 12.40	QUICK FIRE DEBATE	
	<i>Chairs: James McCaslin & Simon Neequaye & Nuno Dias</i>	
	Early amputation and rehabilitation is preferable to multiple interventions in patients with chronic limb threatening ischaemia who have poor treatment options	
	FOR: <i>Paddy Coughlin, Consultant Vascular Surgeon, Leeds</i>	AGAINST: <i>Rob Davies, Consultant Vascular Surgeon, Leicester</i>
12.40– 13.45	LUNCH	
13.45 – 14.30	FOCUS SESSION: SHOULD I TURN THIS PATIENT DOWN?	
	<i>Chairs: Rao Vallabhaneni & Dave Bosanquet</i>	
	CPEX testing and its applicability to endovascular procedures	
	<i>Mike Grocott, Professor of Anaesthesia and Critical Care Medicine, University of Southampton</i>	
	How much better can you make people better for surgery	
	<i>Judith Partridge, Consultant Geriatrician (perioperative medicine for older people undergoing surgery), Guy's & St Thomas' Hospital, London</i>	
	Who should be turned down and contemporary UK turn down rates	
	<i>Pete Holt, Consultant Vascular Surgeon, St George's Hospital, London</i>	
14.30 – 15.05	ABSTRACT SESSION 2 (4+2 minutes)	
	<i>Chairs: Murray Flett & Rao Vallabhaneni</i>	
14.30 – 14.36	Covered endovascular reconstruction of aortic bifurcation (CERAB) - our initial results from a regional centre	
	Uday Pullabattla Venkata , Alex Vesey University Hospital Hairmyres, Glasgow	

14.36 – 14.42	The level of disease is associated with risk of ipsilateral major amputation after endovascular revascularisation for peripheral arterial disease Panagiota Birmpili^{1,2}, Robin Williams³, Eleanor Atkins^{1,2}, Qiuju Li^{1,4}, Amundeep Johal¹, Sam Waton¹, Arun Pherwani⁵, Jonathan Boyle⁶, Ian Chetter^{7,2}, David Cromwell^{1,4} ¹Clinical Effectiveness Unit, Royal College of Surgeons of England, London ²Hull York Medical School, Hull ³Department of Interventional Radiology, Freeman Hospital, Newcastle-upon-Tyne ⁴Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London ⁵Staffordshire & South Cheshire Vascular Network, Royal Stoke University Hospital, Stoke-on-Trent ⁶Cambridge Vascular Unit, Cambridge University Hospitals NHS Trust, Cambridge ⁷Academic Vascular Surgical Unit, Hull University Teaching Hospitals NHS Trust, Hull
14.42 – 14.48	Antithrombotic therapy for aortic and peripheral artery aneurysms: a systematic review and meta-analysis Kitty Hiu Fung Wong^{1,2}, Petar Zlatanovic³, David Bosanquet⁴, Victor Aboyans⁵, Athanasios Saratzis⁶, Stavros Kakkos⁷, Christopher Twine^{1,2} ¹University of Bristol, Bristol ²North Bristol NHS Trust, Bristol ³Clinical Center of Serbia, Belgrade, Serbia ⁴Aneurin Bevan NHS University Health Board, Newport ⁵Dupuytren University Hospital, Limoges, France ⁶University of Leicester, Leicester ⁷University of Patras Medical School, Patras, Greece
14.48 – 14.54	Lower limb ischaemia (LLI): An infodemiological scoping analysis Tim Griffiths¹, Fabio Stocco¹, Marc Bailey², Patrick Coughlin¹ ¹Leeds Teaching Hospital NHS Trust, Leeds ²University of Leeds, Leeds
14.54 – 15.00	Revascularization outcomes of COVID-19 associated Acute Limb Ischemia Mahmood Kabeil¹, Max Wohlaue¹, Ethan Moore¹, Nikolai Harroun¹, Riley Gillette¹, Shelbi Boggs¹, Raghu Motaganahalli², Dejah Judelson³, Varuna Sundaram⁴, Nicolas Mouawad⁵, Marc Bonaca⁶, Robert Cuff⁷ ¹University of Colorado Anschutz Medical Campus, Colorado, USA ²Indiana University School of Medicine, Indiana, USA ³University of Massachusetts Chan Medical School, Massachusetts, USA ⁴Weill Cornell Medicine, NY, USA ⁵McLaren Health System, Michigan, USA ⁶CPC Clinical Research, Colorado, USA ⁷Spectrum Health, Michigan, USA

Thursday 23rd June

15.05 – 15.25	SOCIETY SPONSOR: SHOCKWAVE MEDICAL
	<i>Chairs: Murray Flett & Emma Wilton</i>
	Why I choose IVL in calcium
	<i>Athanasios Saratzis, Consultant Vascular Surgeon, Leicester</i>
15.25 – 15.45	GUEST LECTURE (15+5 minutes)
	<i>Chairs: Emma Wilton & Paul Moxey</i>
	Deep venous treatment in 2022
	<i>Andy Wigham, Consultant Interventional Radiologist, Oxford University Hospitals</i>
15.45 – 16.15:	TEA
16.15 – 16.45	ENDOVASCULAR TECHNOLOGIES: - HOW I DO ... (5+2 minutes)
	<i>Chairs: James McCaslin & Daniela Branzan</i>
	Laser fenestrations
	<i>Nuno Dias, Professor of Vascular Surgery, Malmö-Lund University, Sweden</i>
	Steerable sheaths and what is possible
	<i>Nikos Tsilimparis, Head of Vascular Surgery, LMU Klinikum, Munich</i>
	Atherectomy
	<i>Athanasios Saratzis, Consultant Vascular Surgeon, Leicester</i>
16.45 – 17.45	AORTIC PRIZE ABSTRACT SESSION (6+3 minutes)
	<i>Chairs: Martin Claridge, Simon Neequaye & Andres Schanzer</i>
16.45 – 16.54	Fractured Proximal Nitinol Ring in Fenestrated Anaconda Device: A multi-centre case series
	Tamer El-Sayed¹ , Asef Zahed ¹ , James McCaslin ¹ , Robin Williams ¹ , Peter Bungay ² , Sandip Nandhra ¹
	¹ The Northern Vascular Centre, Freeman Hospital, Newcastle ² The Royal Derby Hospital, Derby
16.55 – 17.04	The utility of post EVAR sac size change in informing the risk of future endograft failure
	Bilal Azhar , James Budge, Arsalan Wafi, Ian Loftus, Peter Holt St Georges Vascular Institute, London
17.05 – 17.14	Limb occlusion after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
	Melvinder Basra^{1,2} , Purvez Hussain ² , Sebastian Ho ¹ , Mimi Li ² , Shreya Kulkarni ¹ , Matthew Armon ¹ , Sohail Choksy ²
	¹ Norfolk & Norwich University Hospital, Norwich ² Colchester Hospital, Colchester

Thursday 23rd June

17.15 – 17.24	Is a 14-day delay necessary when treating Uncomplicated Type B Aortic Dissection (UTBAD) with Thoracic Endovascular Aneurysm Repair (TEVAR)? A systematic review and meta-analysis Shaneel Patel¹ , Martin Hossack ¹ , Richard Jackson ² , Srinivasa Rao Vallabhaneni ¹ ¹ Liverpool University Hospitals NHS Foundation Trust, Liverpool ² Liverpool Clinical Trials Centre, Liverpool
17.25 – 17.34	Medium term follow up of 254 BeGraft Peripheral stents used as bridging stents in fenestrated endovascular aneurysm repair (FEVAR) Jonathan Nicholls , Graham Collin, Neil Collin, Peter Mezes, Marcus Brooks, Paul Bevis Southmead Hospital, Bristol
17.35 – 17.44	Sex-specific differences in pre-operative standard of care for infra-renal AAA repair and association with peri-operative major adverse cardiovascular events and death Anna Louise Pouncey¹ , Guy Martin ¹ , Colin Bicknell ¹ , Michael Sweeting ² , Janet Powell ¹ ¹ Imperial College London, London ² University of Leicester, Leicester
17.45 – 18.00	THE PRESIDENT'S DEBATE <i>Introduced by Rao Vallabhaneni</i> Only randomised controlled trials will provide the required evidence to justify uptake of innovative endovascular technologies FOR: Colin Bicknell AGAINST: Jonathan Boyle
19.15	DRINKS RECEPTION
20.00	DINNER

08.45 – 09.20	ABSTRACT SESSION 3 (4+2 minutes)
	<i>Chairs: Dave Bosanquet & Patrick Chong</i>
08.45 – 08.51	Outcomes following use of bovine pericardium (xenoprosthetic) grafts for aortic reconstruction of mycotic aneurysms and infected aortic grafts: a systematic review and meta-analysis
	Samuel Grills¹, Nadia El-Diaz¹, Abigail Walker-Jacobs², Philip Stather² ¹ University of East Anglia, Norwich ² Norfolk and Norwich University Hospital, Norwich
08.52 – 08.59	Acute kidney injury following endovascular intervention for peripheral artery disease
	Emmanuel Katsogridakis¹, Prakash Saha², Athanasios Diamantopoulos², Nikolaos Saratzis³, Robert Davies⁴, Matt Bown¹, Athanasios Saratzis¹ ¹ University of Leicester, Leicester ² Guy's & St. Thomas's NHS Trust, London ³ Papageorgiou General Hospital, Thessaloniki, Greece ⁴ Leicester Vascular Institute, Leicester
09.00 – 09.06	Outcome of surgical revascularisation of Acute upper limb ischemia: A Single Centre Experience
	Ayman Elsayed, Philip Stather, Ishtiaq Aziz NNUH, Norwich
09.07 – 09.13	A systematic review and meta-analysis of Randomized Controlled Trials comparing thermal versus non-thermal endovenous ablation in superficial venous incompetence
	Noman Shahzad, Mohamed Elsherif Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
09.14 – 09.20	Comparison of procedures pre- and post-hybrid theatre in a UK arterial vascular surgery centre
	George Ninkovic-Hall, David Riding, Dana Sochorova, Simon Neequaye Liverpool University Hospitals NHS Foundation Trust, Liverpool
09.20 – 09.35	THE BRITISH SOCIETY OF ENDOVASCULAR THERAPY - Conformable Endovascular Aneurysm Repair (BSET-CLEVAR) Registry
	<i>Chair: Bijan Modarai</i>
	First presentation of the early imaging results
	<i>Speakers: Colin Bicknell & Rao Vallabhaneni</i>

Friday 24th June

09.35 – 09.45	GOLD SPONSOR PRESENTATION: TERUMO AORTIC	
	<i>Chairs: Bijan Modarai & Andres Schanzer</i>	
	Customisation options for Relay Platform in Clinical Practice?	
	<i>Simon Neequaye, Consultant Vascular Surgeon, Liverpool</i>	
09.45 – 10.05	GUEST LECTURE (15+5 minutes)	
	<i>Chairs: Bijan Modarai & Andres Schanzer</i>	
	State of the art update: Endovascular aortic arch repair	
	<i>Nikos Tsilimparis, Head of Vascular Surgery, LMU Klinikum, Munich</i>	
10.05 – 10.15	GOLD SPONSOR PRESENTATION: ENDOLOGIX	
	<i>Chairs: Martin Claridge & Pete Holt</i>	
	Mid to long term durability of EVAR performed using a polymer based aortic endograft system	
	<i>Hiren Patel, Consultant Vascular Surgeon, Manchester</i>	
10.15 – 10.35	QUICK FIRE DEBATE (7+7+6 minutes)	
	<i>Chairs: Martin Claridge & Pete Holt</i>	
	Complex endovascular repair offers superior durability: This should be used in preference to standard EVAR for most patients	
	FOR: <i>Nuno Dias</i>	AGAINST: <i>Daniela Branzan</i>
10.35 – 11.15	COFFEE	
11.15 – 11.25	GOLD SPONSOR PRESENTATION: ABBOTT	
	<i>Chairs: Emma Wilton & Paul Bevis</i>	
	Endovascular treatment of the CFA	
	<i>Lieven Maene, Aalst, Belgium</i>	
11.25 – 11.45	VASCULAR SOCIETY SESSION	
	<i>Chairs: Jonathan Boyle & Rachel Bell</i>	
	The impact of NICE: Guidelines on AAA management	
	<i>Jonathan Boyle, President, The Vascular Society</i>	
	Headlines from POVS 2021	
	<i>Marcus Brooks, Honorary Secretary, The Vascular Society</i>	
	The Aortic Dissection Toolkit	
	<i>Rachel Bell, President Elect, The Vascular Society</i>	

11.45 – 11.55	GOLD SPONSOR PRESENTATION: ARTIVION
	<i>Chairs: Chris Twine and Paul Moxey</i>
	The rise of inner branches
	<i>Daniela Branzan, Head of Vascular Surgery, University Medicine Leipzig</i>
11.55 – 12.45	PERIPHERAL PRIZE ABSTRACT SESSION (6+3 minutes)
	<i>Chairs: Chris Twine and Paul Moxey & Nuno Dias</i>
11.55 – 12.04	Eligibility of COMmoN FEmoral artery atheroSclerotic diSease for endovascular treatment – the CONFESS study
	Gabriela Kaneta¹, Shehzeen Husain¹, Liam Musto², Tatiana Hamakarim³, Ahmed Elsharkawi¹, Sofia Littlejohn², Jessica Helm², Athanasios Saratzis², Hany Zayed¹ ¹ Guy's and St Thomas' NHS Foundation Trust, London ² Department of Cardiovascular Sciences, University of Leicester, Leicester ³ King's College, London
12.05 – 12.14	Inferior vena cava reconstruction: A single centre experience
	Chiragh Shah, Andrew Wigham, Emma Wilton Thames Valley Vascular Network, Oxford
12.15 – 12.24	Medium term outcomes in patients undergoing atherectomy and anti-restenotic therapy vs. bypass for long infrainguinal in-stent occlusions
	Badri Vijaynagar, Emmanuel Katsogridakis, Athanasios Saratzis Leicester Vascular Institute, Leicester
12.25 – 12.34	A Single Centre Early Experience of Directional Atherectomy in Managing Lower Limb Ischaemia
	Tamer El-Sayed, Albagir Altahir, Matthew Thomas, James McCaslin, Craig Nesbitt The Northern Vascular Centre, Freeman Hospital, Newcastle
12.35 – 12.44	Perception and acceptability of open vs endovascular treatment of common femoral artery disease: Barriers and facilitators for randomised controlled trials
	Gabriela Kaneta¹, Athanasios Saratzis², Hany Zayed¹ ¹ Guy's and St Thomas' NHS Foundation Trust, London ² Department of Cardiovascular Sciences, University of Leicester, Leicester
12.50 – 13.10	CHEE SOONG MEMORIAL LECTURE: What are we all doing here?
	John Brennan, Consultant Vascular Surgeon, Liverpool
	<i>Introduced by Colin Bicknell</i>
13.10 – 13.20	PRESENTATION OF PRIZES AND CLOSE
13.25 – 14.30	LUNCH

GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis



Flexible Strength. Proven Success.

- 100% restoration of lumen diameter¹
- 100% maintenance of stent length¹
- 100% stent delivery at target site with no stent dislodgement¹
- 96.9% primary patency¹

See flexible strength in action:

goremedical.com/eu/vbx-expands

1. Bismuth J, Gray BH, Holden A, Metzger C, Panneton J; VBX FLEX Study Investigators. Pivotal study of a next-generation balloon-expandable stent-graft for treatment of iliac occlusive disease. *Journal of Endovascular Therapy* 2017;24(5):629-637.

 Consult Instructions
for Use
eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. **Rx Only**

Products listed may not be available in all markets.

GORE, VBX, VIABAHN and designs are trademarks of W. L. Gore & Associates.
© 2021 W. L. Gore & Associates GmbH 21203761-EN JUNE 2021



ABSTRACT SESSIONS



Association of hospital volume with perioperative mortality of endovascular repair of complex aortic aneurysms – a nationwide cohort study

Jorg Lucas de Bruin¹, Anna Alberga^{1,2}, Hence Verhagen¹

¹Erasmus Medical Center, Rotterdam, Netherlands

²DICA, Leiden, Netherlands

Background

Endovascular treatment with fenestrated (FEVAR) or branched (BEVAR) endografts is progressively used for excluding complex aortic aneurysms (complex AAs). It is unclear if a volume-outcome association exists in endovascular treatment of complex AAs (complex EVAR).

Methods

All patients prospectively registered in the Dutch Surgical Aneurysm Audit who underwent complex EVAR (FEVAR or BEVAR) between January 2016 and January 2020 were included. The effect of annual hospital volume on perioperative mortality was examined using multivariable logistic regression analyses. Patients were stratified into quartiles based on annual hospital volume to determine hospital volume categories.

Results

We included 694 patients (539 FEVAR patients, 155 BEVAR patients). Perioperative mortality following FEVAR was 4.5% and 5.2% following BEVAR. Postoperative complication rates were 30.1% and 48.7%, respectively. The first quartile hospitals performed <9 procedures/yr; second, third, and fourth quartile hospitals performed 9-12, 13-22, and ≥23 procedures/yr. The highest volume hospitals treated the significantly more complex patients. Perioperative mortality of complex EVAR was 9.1% in hospitals with a volume of <9, and 2.5% in hospitals with a volume of ≥13 (P=0.008). After adjustment for confounders, an annual volume of ≥13 was associated with less perioperative mortality compared to hospitals with a volume of <9.

Conclusions

Data from this nationwide mandatory quality registry shows a significant effect of hospital volume on perioperative mortality following complex EVAR, with high volume complex EVAR centers demonstrating lower mortality rates.

Mortality associated with delayed vascular surgery during the COVID-19 pandemic disproportionately affects female patients

Ethan Moore¹, Max Wohlauser¹, Mahmood Kabeil¹, Riley Gillette¹, Nicolas Mouawad², Jason Chuen³, Joseph Mills⁴, Judith Lin⁵, London Guidry Lyons⁶, Issam Koleilat⁷, Leigh Ann O'Banion⁸, Robert Cuff⁹

¹University of Colorado Anschutz Medical Campus, Aurora, USA

²McLaren Health System, Bay City, USA

³Austin Health, Heidelberg, Australia

⁴Baylor College of Medicine, Houston, USA

⁵Michigan State University, East Lansing, USA

⁶Louisiana State University Program, New Orleans, USA

⁷RWJBarnabas Health, Toms River, USA

⁸University of California San Francisco (UCSF) Fresno, Fresno, USA

⁹Spectrum Health, Grand Rapids, USA

Background

The COVID-19 pandemic has caused a rapid and widespread postponement of scheduled vascular surgical operations. The objective of this study was to determine the impact of surgery postponement.

Methods

A REDCap database recorded the outcomes of patients whose scheduled vascular surgeries were delayed during the pandemic. An interim data analysis of patients in North America who died before their postponed surgeries was performed.

Results

The 908 patients included in the analysis had the following conditions: 157 (17.3%) aortic, 63 (6.94%) carotid, 230 (25.4%) peripheral artery disease (PAD), 248 (27.3%) end-stage renal disease (ESRD), and 210 (23.2%) venous. Nineteen patients (2.09%) died while awaiting surgery. Seven (36.8%) were male and 12 (63.2%) were female. The average length of surgical delay to the time of death was 94.9 days (+/- 90.1 SD). Of the patients with aortic disease, 3.82% died before surgery. Of the patients with carotid disease, 3.17% died before surgery. Of the patients with PAD, 2.17% died before surgery. Of the patients with ESRD, 2.42% died before surgery. Zero patients with venous disease died before surgery. Two (50.0%) of the four patients with abdominal aortic aneurysms (AAAs) greater than 8.1 cm died before their scheduled surgeries.

Conclusions

One out of 50 (2.0%) patients with vascular disease whose surgeries were postponed died waiting for surgery. Patients who died were disproportionately female. Half of the patients with AAAs greater than 8.1 cm died waiting for surgery, which is higher than the annual estimated risk for aneurysm rupture. Further investigation is needed.

Social deprivation and the association with survival following Fenestrated Endovascular Aneurysm Repair

Ehsanul Choudhury, *James Rammell*, Nikesh Dattani, James McCaslin,
James Prentis, Sandip Nandhra
Northern Vascular Centre, Newcastle

Background

Social deprivation is associated with poor clinical outcomes. It is known to have an impact on length of stay and post-operative mortality across a number of other surgical specialties. This study evaluates the impact of social deprivation on outcomes following fenestrated endovascular aneurysm repair (FEVAR).

Methods

All elective FEVARs performed between 2010-2018 at a tertiary vascular centre were analysed. Deprivation data was sourced from the English indices of deprivation (IMD) 2019, by postcode. Primary outcome was overall survival. Secondary outcomes included length of hospital stay (LOS) and complications.

Results

Some 132 FEVAR patients were followed-up for 3.7 (SD 2.2) years. Fifty-seven patients lived in areas with high levels of deprivation, 34 in areas with moderate deprivation and 41 in areas with the lowest level of deprivation. Groups were comparable for age, BMI, AAA diameter and co-morbidity. Kaplan-Meier analysis demonstrated significantly poorer survival for patients living in areas with high levels of deprivation (IMD 1-3) ($p=0.03$). Mortality was comparable for IMD 4-6 and 7-10 groups. Patients from the most deprived areas had longer hospital stay (6 days (4-9) vs. 5 (3-7) $p=0.005$) and higher all-cause complication rates (21 (36.8%) vs. 14 (18.4%) $p=0.02$). Decreasing IMD was associated with worse survival (HR -0.85 (0.75-0.97) ($p=0.02$)).

Conclusions

Social deprivation was associated with increased mortality, length of stay and all-cause complication rates in patients undergoing FEVAR for complex abdominal aortic aneurysm (AAA). These results may help direct pre-optimisation measures to improve outcomes in higher risk sub-groups.

Initial UK experience using a dedicated venous mechanical thrombectomy device in patients presenting with acute deep vein thrombosis

Chiragh Shah, Emma Wilton, Andrew Wigham
Thames Valley Vascular Network, Oxford

Background

Interventional treatment of deep vein thrombosis requires effective thrombus clearance and venoplasty/stenting of underlying stenoses. Mechanical techniques for thrombus clearance mitigate bleeding risks, and can enable single-sitting treatment. Limitations with current mechanical devices include embolization, poor thrombus clearance, and limited efficacy on sub-acute thrombus. We audit our results in treating acute and sub-acute deep vein thrombosis using the Inari Medical ClotTriever mechanical thrombectomy device.

Methods

Prospective data for all cases of venous mechanical thrombectomy using the Inari Medical ClotTriever device in our tertiary referral centre was collected.

Results

14 patients (median age 52 years) have undergone treatment with the Inari Medical ClotTriever mechanical thrombectomy device in our centre between March 2021 and February 2022. The estimated history-based mean age of thrombus was 12 days (range 2-34 days). 12 cases had unilateral iliofemoral venous thrombosis. 2 cases had bilateral iliofemoral venous thrombosis extending into the infrarenal IVC. Only 50% of procedures were undertaken under general anaesthesia. The median number of device passes was 6 (range 2-14). Mean thrombus clearance was 85% (range 80-90%). Stenting for underlying venous stenosis was completed in the same sitting in 10 cases. In those, a mean of 1.7 stents (range 1-4) were placed.

Conclusions

Preliminary data has shown the device to offer a safe and effective single-sitting, thrombolytic-free option, with no major access site complications. It is well tolerated, with half of procedures completed successfully under local anaesthesia. The reduced incidence of stenting, particularly in the sub-acute patient group, is a promising early signal.

Small abdominal aortic aneurysms in the over 85s ... Do we need to survey them?

Sally Maryosh, Brenig Gwilym, Danielle Lowry, Madlen Dewi, Peter Lewis, David McLain, David Lewis, David Bosanquet

Department of Vascular Surgery, Aneurin Bevan Health Board Hospitals, Wales

Background

The benefit of surveillance of Abdominal Aortic Aneurysms (AAAs) for patients aged ≥ 85 with small AAAs is questionable. Despite recent research showing few patients ≥ 85 with small AAAs undergo treatment, no guidelines exist for determining which patients should be removed from surveillance. The aim of the study was to explore whether patients aged ≥ 85 with small AAAs, when contacted by a vascular surgeon, opted to remain under surveillance, or not.

Methods

Telephone consultations with patients aged ≥ 85 on local AAA surveillance with AAAs sized 3.0–5.0cm were undertaken by a vascular consultant/registrar. Information regarding time since diagnosis, frailty, understanding of the surveillance program, and treatment was gathered. After explaining the pros and cons of ongoing surveillance, patients decided if they wished to continue surveillance, and if they wanted to be considered for AAA treatment at threshold (i.e. 5.5cm) or in the context of rupture.

Results

25 patients were contacted. The mean age was 86 years, the mean AAA size was 4.8cm (range 3.2–4.9 cm), and the mean time since diagnosis was 4.8 years (range 1–10 years). Twelve patients (41%) decided to leave surveillance. Eleven patients reached an agreement about management of potential future rupture; six did not want treatment at threshold. Five patients (17%) reported difficulty attending screening, with all but one opting to leave the surveillance programme.

Conclusions

Almost one half of those aged ≥ 85 with a small/medium AAA opted to withdraw from surveillance when asked. This represents a significant cost savings for surveillance programmes.

EVAR in octogenarians is safe: A meta-analysis and meta-regression

Charles Hallett¹, Yousef Yousef², Kunal Namjoshi¹, Nina Al-Saadi²,
Isabel O'Shea³, Robert Hicks², David Sidloff⁴

¹University Hospitals of Leicester, Leicester

²Northampton General Hospital, Northampton

³North Middlesex University Hospital, London

⁴Queen's Medical Centre, Nottingham

Background

The safety and durability of endovascular aneurysm repair (EVAR) in the elderly is contentious. This review aims to evaluate the post-operative and long term outcomes in this population.

Methods

Standard PRISMA guidelines were followed and qualitative assessment of studies. Meta-analysis was performed using Mantel – Haenszel and weighted summary proportions with meta-regression utilised where possible.

Results

25 observational studies were included for meta-analysis totalling 40,641 octogenarians with an average age of 83.5 years. Octogenarians were more likely to be female, non-smokers, comorbid and have a larger aneurysmal diameter. Octogenarians had a pooled perioperative mortality of 2.48% (CI 2.1 - 2.95) increasing to 9.14% (CI 8.32 - 10.0) and 52.9% (CI 38.7 - 66.8) at 1 and 5 Years respectively. Meta-regression suggests an all cause mortality approaching 10% per year (10.58, R² 0.74). Perioperative complications were 5.2% (CI 3.66 - 6.96), 2.83% (CI 1.49 - 4.81) and 3.55% (CI 2.12 - 5.33) suggesting reasonable rates of cardiac, pulmonary and renal complications respectively. 19.8% (CI 13.9 - 26.4) of patients had an endoleak, however, only 3.12% (CI 2.22 - 4.16) required re-intervention within 30 days. No difference was seen in rates of post-operative re-intervention, sac diameter increase or rupture.

Conclusions

EVAR is safe and durable with reasonable peri-operative and long-term outcomes. This highlights the importance of EVAR as a treatment choice in this group of patients.

Covered endovascular reconstruction of aortic bifurcation (CERAB) - our initial results from a regional centre

Uday Pullabattla Venkata, Alex Vesey
University Hospital Hairmyres, Glasgow

Background

CERAB is a novel technique to treat Aorto-iliac occlusive disease (AIOD) offering an alternative approach to open Aorto-bifemoral bypass or conventional endovascular procedures like kissing iliac stents. It involves reconstructing the aortic bifurcation endovascularly with preservation of more natural flow dynamics. We present our initial results from a single centre with this novel approach.

Methods

This study was carried out through analysing our prospective database of all patients who underwent CERAB between July 2012- March 2021. We used Rutherford's classification for chronic ischaemia to grade the pre-operative clinical severity of the lesion and a detailed review of radiological images for lesion characteristics. Mean follow-up period was 14 months.

Results

There were 19 patients in total with a median age 62. 18 of them had a Trans-Atlantic inter-society consensus (TASC) D lesion. The procedure was successfully carried out in all patients. Two patients had intra-operative complications in the form of ruptured external iliac artery and acute aortic dissection with renal artery stenosis, both were managed successfully with stents. Median length of stay was 2.5 days and there were no reported deaths or limb loss during the initial 30 days or during the follow-up period. Two patients however had stent occlusions during follow-up needing iliac thrombectomy and Fem-Fem crossover graft. All patients had subjective symptom improvement during follow-up.

Conclusions

CERAB is an excellent alternative to conventional procedures for AIOD in selected patients with acceptable short-medium term outcomes.

The level of disease is associated with risk of ipsilateral major amputation after endovascular revascularisation for peripheral arterial disease

Panagiota Birmpili^{1,2}, Robin Williams³, Eleanor Atkins^{1,2}, Qiuju Li^{1,4}, Amundeep Johal¹, Sam Waton¹, Arun Pherwani⁵, Jonathan Boyle⁶, Ian Chetter^{7,2}, David Cromwell^{1,4}

¹Clinical Effectiveness Unit, Royal College of Surgeons of England, London

²Hull York Medical School, Hull

³Department of Interventional Radiology, Freeman Hospital, Newcastle-upon-Tyne

⁴Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London

⁵Staffordshire & South Cheshire Vascular Network, Royal Stoke University Hospital, Stoke-on-Trent

⁶Cambridge Vascular Unit, Cambridge University Hospitals NHS Trust, Cambridge

⁷Academic Vascular Surgical Unit, Hull University Teaching Hospitals NHS Trust, Hull

Background

Our aim was to evaluate the association between the level of disease and 1-year outcomes after endovascular revascularisation for peripheral arterial disease (PAD).

Methods

All patients over 40 years old, who underwent endovascular revascularisation for PAD from January 2017 to December 2019 were extracted from Hospital Episode Statistics. Hybrid procedures and patients with revascularisations or major amputations 3 years prior to the index event were excluded. Level of disease was defined as the most distal treated vessel. The effect of level of disease on 1-year ipsilateral major lower limb amputation (MLLA) and mortality was modelled using two-level multinomial logistic regression, to account for patient characteristics and hospital of treatment.

Results

The study included 32,415 patients (65.4% men, 44.4% with diabetes). The most distal arteries treated were iliac (29.9%), femoral (45.0%), popliteal (10.3%) and crural (14.8%), and 14.3% of procedures included multiple vessels. Re-intervention rate at 30-days was 4.3% and at 1-year 15.1%. The unadjusted 1-year MLLA rate was 4.5% (95%CI 4.2-4.7%) and 1-year mortality 14.5% (14.1-14.8%). Adjusting for age, gender, comorbidities, frailty, deprivation, admission mode, tissue loss and number of treated vessels, distal disease was associated with significantly higher risk of 1-year MLLA (crural 4.5% [3.8-5.2%] vs. iliac: 2.2% [1.8-2.5%] and femoral 3.0% [2.6-3.4%], $p < 0.001$) but not 1-year mortality. Independent predictors of 1-year MLLA were male gender, younger age, diabetes, tissue loss, emergency admission, increased frailty and increased deprivation.

Conclusions

The level of disease is associated with 1-year MLLA risk and should be considered during patient selection and for risk-adjusted outcome reporting.

Antithrombotic therapy for aortic and peripheral artery aneurysms: A systematic review and meta-analysis

Kitty Hiu Fung Wong^{1,2}, Petar Zlatanovic³, David Bosanquet⁴, Victor Aboyans⁵, Athanasios Saratzis⁶, Stavros Kakkos⁷, Christopher Twine^{1,2}

¹University of Bristol, Bristol

²North Bristol NHS Trust, Bristol

³Clinical Center of Serbia, Belgrade, Serbia

⁴Aneurin Bevan NHS University Health Board, Newport

⁵Dupuytren University Hospital, Limoges, France

⁶University of Leicester, Leicester

⁷University of Patras Medical School, Patras, Greece

Background

The role of antithrombotic therapy in aneurysm progression and outcomes following surgical or endovascular intervention is unclear.

Methods

A systematic review and meta-analysis was performed. Medline, Embase, and CENTRAL databases were searched. Randomised-controlled trials and observational studies investigating the effect of antithrombotic therapy on clinical outcomes for patients with aortic or extracranial peripheral arterial aneurysms were included. Aneurysm growth rate, major adverse cardiovascular or limb events, mortality, endoleaks, re-intervention rates, and other outcomes were captured.

Results

Fifty-seven studies (26 antiplatelets, 12 anticoagulants, 16 any antithrombotic agent(s), 2 intra-operative heparin) involving 121,451 patients were included. Aspirin reduced growth rates of aortic aneurysms under surveillance (mean difference -0.9mm/y, 95%CI -1.74 to -0.07, $p=0.03$; GRADE certainty: moderate). For aortic aneurysms undergoing intervention, antithrombotics increased 30-day mortality (odds ratio [OR] 2.30, 95%CI 1.51 to 3.51, $p<0.001$; GRADE certainty: moderate). Antiplatelets reduced long-term all-cause mortality (hazard ratio [HR] 0.84, 95%CI 0.76 to 0.92, $p<0.001$; GRADE certainty: moderate), whilst anticoagulants increased this risk (HR 1.64, 95%CI 1.14 to 2.37, $p=0.008$; GRADE certainty: very low). Anticoagulants increased incidence of endoleaks under 3 years, and re-intervention rates ($p<0.05$ for all). Antithrombotic agents did not significantly affect rupture rates in aortic aneurysms. Meta-analysis was not possible for ruptured aneurysms and popliteal aneurysms.

Conclusions

There is moderate quality evidence that aspirin reduced aneurysm growth rates. Antiplatelet agents reduced all-cause mortality in aneurysms after intervention; whilst anticoagulants increased this risk, along with endoleaks and re-interventions. Well-designed trials are required to determine therapeutic benefits of antithrombotic agents for patients with aneurysms.

Lower limb ischaemia (LLI): An infodemiological scoping analysis

Tim Griffiths¹, Fabio Stocco¹, Marc Bailey², Patrick Coughlin¹

¹Leeds Teaching Hospital NHS Trust, Leeds ²University of Leeds, Leeds

Background

Patients are increasingly using the internet to obtain medical information. This study aims to detail the search characteristics for keywords relevant to LLI.

Methods

Google TrendsTM provides data on search terms characterised by defined time-intervals. It provides relative search volumes (RSV), (0: data availability inadequate - 100: highest keyword popularity). We interrogated Google TrendsTM for the 5-year period (UK based 18/02/2017 – 18/02/2022). Median RSV values were calculated.

We undertook the following searches comparing different keywords:

1. "intermittent claudication (IC)", "peripheral arterial disease (PAD)", "critical limb threatening ischaemia (CLTI)", "lower limb ischaemia (LLI)"
2. "intermittent claudication" and "poor circulation"
3. "diabetic foot ulcer", "foot ulcer", "critical limb threatening ischaemia", "gangrene", "black toe"
4. "intermittent claudication", "abdominal aortic aneurysm", "carotid endarterectomy"
5. "intermittent claudication", "heart attack", "stroke"

Results

1. Median RSV was highest for the search term IC (34.5) when compared to PAD (28), CLTI (0) and LLI (0 – $p<0.001$).
2. Median RSV for "poor circulation" was higher than for IC (10 vs. 45 – $p<0.001$).
3. Median RSV was highest for "Black toe" (17) and then "gangrene" (8), "foot ulcer" (2), "diabetic foot ulcer" (1) and CLTI (0 – $p<0.001$).
4. Median RSV score was higher for abdominal aortic aneurysm (41) than IC (15) or carotid endarterectomy (12 – $P<0.001$).
5. Median RSV for stroke and heart attack were higher than for IC (39 & 16 vs. 0 – $p<0.001$).

Conclusions

LLI is common yet is not searched for as often as other arterial conditions. Better use of lay terms may help inform our patient population.

Revascularization outcomes of COVID-19 associated acute limb ischemia

Mahmood Kabeil¹, Max Wohlaue¹, **Ethan Moore¹**, Nikolai Harroun¹, Riley Gillette¹, Shelbi Boggs¹, Raghu Motaganahalli², Dejah Judelson³, Varuna Sundaram⁴, Nicolas Mouawad⁵, Marc Bonaca⁶, Robert Cuff⁷

¹University of Colorado Anschutz Medical Campus, Colorado, USA.

²Indiana University School of Medicine, Indiana, USA.

³University of Massachusetts Chan Medical School, Massachusetts, USA.

⁴Weill Cornell Medicine, NY, USA.

⁵McLaren Health System, Michigan, USA.

⁶CPC Clinical Research, Colorado, USA.

⁷Spectrum Health, Michigan, USA

Background

Acute limb ischemia (ALI) is one of the catastrophic thrombotic manifestations of COVID-19.

Methods

An interim analysis on 46 patients with COVID-19 associated ALI submitted to the Vascular Surgery COVID-19 Collaborative (VASCC) database from 10 USA institutions.

Results

In our cohort, the mean age was 62.2 years, 73.9% of patients were male, 67.4% were white, and 93.5% met Rutherford's criteria classes 2 or 3. On average, patients developed ALI 12.2 days after a positive COVID test.

Open thrombectomy attempted in 50.0%, endovascular lysis or thrombectomy in 23.9%, bypass in 2.2%, and wasn't attempted in 23.9%. Revascularization was successful in 41.3% with symptom resolution, 15.2% with limb salvage but persistent symptoms, 4.3% ultimately had a major amputation, 4.3% required reoperation, and unsuccessful revascularization in 10.9%. Average hospital stay was 13.2 days and average ICU stay was 4.66 days. Overall, in-hospital mortality was 21.7%, major amputation in 8.7%, stroke in 8.7%, major limb intervention in 6.5%, and sepsis in 2.2%.

Successful revascularization rate was 62.5% in the open surgery group (24 patients) versus 36.4% in the endovascular group (11 patients) with shorter ICU stay in the open group (mean=3.24 days) than the endovascular group (mean=8.60 days). Within the 11 patients with no revascularization, 36.4% died, 18.2% had a major amputation, 9.1% had a pulmonary embolism, and 9.1% had a stroke.

Conclusions

COVID-19 associated ALI can be managed successfully with endovascular or open surgery. In our cohort, open revascularization had reduced ICU stay with improved limb salvage than the endovascular group.

Fractured proximal nitinol ring in fenestrated Anaconda device: A multi-centre case series

Tamer El-Sayed¹, Asef Zahed¹, James McCaslin¹, Robin Williams¹, Peter Bungay², Sandip Nandhra¹

¹The Northern Vascular Centre, Freeman Hospital, Newcastle

²The Royal Derby Hospital, Derby, Derby

Background

There is an increase in the number and complexity of aortic aneurysms treated by fenestrated endovascular stent-grafts. The Terumo Aortic Anaconda™ Endovascular Aortic Stent Graft System has been used since 2010 and is one of two widely used platforms. We report a multi-centre case series of Anaconda™ Stent Graft with proximal ring fractures.

Methods

This is a multi-centre retrospective case series of proximal ring fractures in patients who underwent fenestrated endovascular aortic aneurysm repair (FEVAR) with the Anaconda Stent Graft between 2010 and 2021 in two UK tertiary vascular centres (the Freeman Hospital, Newcastle and the Royal Derby Hospital, Derby).

Results

15 patients (median age 68 years [64-88]) out of 253 patients who underwent FEVAR with the Anaconda Stent Graft System, were found to have incidental fractures of the proximal sealing ring on routine surveillance between 23/03/2013 and 12/11/2021. Four cases showed wire fracture from the proximal sealing ring and migration to the surrounding tissue/organs. One patient developed aneurysm sac expansion with type IA due to stent migration and subsequent one fenestration occlusion requiring secondary intervention. Other patients (14 out of 15) did not show stent migration or loss of the proximal sealing zone and are managed conservatively with no clinical harm identified to date.

Conclusions

Early data in this case series highlight the importance of surveillance following aortic endo-graft placement. A wider review across additional centres is required to understand the clinical consequences of stent ring fracture as well as any adverse anatomical prognostic features.

The utility of post EVAR sac size change in informing the risk of future endograft failure

Bilal Azhar, James Budge, Arsalan Wafi, Ian Loftus, Peter Holt
St Georges Vascular Institute, London

Background

A need exists for a marker of therapeutic failure post endovascular aneurysm repair (EVAR), given concerns of late device related complications. We aimed to study the utility of post-EVAR aneurysm sac size change in informing risk prediction models of endograft failure.

Methods

The ENGAGE EVAR registry was retrospectively analysed. Post-operative sac size change was modelled for patients, with reference to observed endograft complications (composite outcome of type 1 or type 3 endoleak, rupture preventing re-intervention or secondary rupture). Kaplan Meier analysis was performed to establish the event free probability of EVAR endograft complications associated with sac size change. Joint Bayesian modelling with K-fold cross validation was used to produce risk predictions of EVAR endograft complications.

Results

Of 1151 patients included for analysis (median follow-up 4.1 years; IQR 2.9-4.7), 60% had sac regression, 30% had a stable sac and 10% had sac expansion post EVAR. The 5-year event-free probability of suffering an endograft complication was 92% (95% CI 90-94), 84% (95% CI 78-90) and 45% (95% CI 35-58) for the sac regression, stable sac, and sac expansion groups respectively. Informed by changing aneurysm diameter post EVAR, a joint Bayesian modelling technique was able to predict the risk of an endograft complication at 5 years with very good discrimination and precision (AUC 0.90, prediction error 0.065).

Conclusions

Sac size change post EVAR is a promising dynamic marker of EVAR durability. Joint Bayesian modelling informed by post-EVAR sac size change provides a novel approach in obtaining risk predictions of endograft related complications.

Limb Occlusion after Endovascular Abdominal Aortic Aneurysm repair (EVAR)

Melvinder Basra^{1,2}, Purvez Hussain², Sebastian Ho¹, Mimi Li², Shreya Kulkarni¹, Matthew Armon¹, Sohail Choksy²

¹Norfolk & Norwich University Hospital, Norwich

²Colchester Hospital, Colchester

Background

Limb occlusion is a potentially serious consequence of EVAR. This case-control study identifies predisposing factors.

Methods

A consecutive series of patients from two centres undergoing EVAR from 2007- 2017 were identified retrospectively. Patient record interrogation allowed collation of demographics, intra- and peri-operative data and surveillance data. The pre-operative CTA was analysed to determine EVAR relevant anatomical data. The primary outcome was occlusion of an EVAR limb.

Results

We analysed a total of 787 patients (702 males; median age 78 years, range 53-94 years). 50 patients reached the primary outcome, resulting in an overall limb occlusion rate of 50/787 (6.35%). Factors predictive of limb occlusion were oversizing by >10% of the native vessel diameter, oversizing of >20% affecting 25/50 (50%), external iliac artery landing zone 12/50 (24%) and post-operative kinking 5/50 (10%). 50 randomly selected controls with similar baseline characteristics were studied. Oversizing of the iliac endograft was found to be significantly greater in the limb occlusion group compared to the controls. This difference was statistically significant according to the Mann-Whitney U test ($p < 0.05$). Iliac tortuosity did not contribute to limb occlusion. Binomial logistic regression excluded statistically significant confounding. The Cook endograft had a 9% limb occlusion rate across sites. Medtronic and Vascutek endografts had 2.4% and 2.5% limb occlusion rates respectively.

Conclusions

Oversizing of EVAR limbs by >10% is a key factor contributing to limb occlusion and the Cook endograft appears more susceptible. Meticulous case planning with judicious oversizing has the potential to change practice.

Is a 14-day delay necessary when treating Uncomplicated Type B Aortic Dissection (UTBAD) with Thoracic Endovascular Aneurysm Repair (TEVAR)? A systematic review and meta-analysis

Shaneel Patel¹, Martin Hossack¹, Richard Jackson², Srinivasa Rao Vallabhaneni¹

¹Liverpool University Hospitals NHS Foundation Trust, Liverpool

²Liverpool Clinical Trials Centre, Liverpool

Background

The optimal timing of early TEVAR for treating UTBAD is unknown. The INSTEAD trial, comparing TEVAR with BMT, did not recruit patients in the first 14 days. However, this early delay risks uncomplicated TBAD becoming complicated, increasing mortality. A systematic review and meta-analysis of comparative outcomes between TEVAR performed in the acute and subacute phases of TBAD was performed.

Methods

A systematic search of MEDLINE was conducted according to PRISMA guidelines. Studies comparing perioperative outcomes between TEVAR performed in the acute and subacute phases of TBAD were included. Subgroup analyses were undertaken for (1) studies reporting uncomplicated TBAD only and (2) studies permitting comparison of "delayed acute phase" treatment (3-14 days) with subacute treatment.

Results

The search yielded 13 retrospective, observational studies (2849 patients). Overall, compared to subacute phase treatment, acute phase TEVAR was associated with higher mortality (RR3.45, 95%CI 2.06-5.79, $p<0.0001$) and stroke (RR2.29, 95%CI 1.31-4.00, $p=0.0036$), but equivalent rates of retrograde dissection, spinal cord ischaemia and reintervention. Across studies reporting on uncomplicated TBAD only, acute phase TEVAR was associated with higher mortality compared to subacute TEVAR (RR3.14, 95%CI 1.37-7.21, $p=0.0068$) but not for other complications. There was no difference in death or complications between TEVAR performed at 3-14 days compared to subacute phase TEVAR.

Conclusions

TEVAR for UTBAD in the acute phase, compared to subacute phase, carries a higher rate of death, but not retrograde dissection, stroke, or spinal cord ischaemia. It may be necessary to wait for only 3 days and not 14 when planning TEVAR.

Medium term follow up of 254 BeGraft Peripheral stents used as bridging stents in fenestrated endovascular aneurysm repair (FEVAR)

Jonathan Nicholls, Graham Collin, Neil Collin, Peter Mezes, Marcus Brooks, Paul Bevis
Southmead Hospital, Bristol

Background

There are no bridging stents approved for use in fenestrated aortic aneurysm repair (FEVAR). We assessed patency and re-intervention in the BeGraft Peripheral stent (Bentley InnoMed GmbH), which is now our bridging stent of choice.

Methods

Data from consecutive elective patients is collected prospectively in a unit-maintained database. All patients with Bentley BeGraft Peripheral bridging stents treated from June 2018 to January 2021 for FEVAR were included. Demographic data, stent specifications & target vessel diameters were collected. Patients with a minimum 12 month follow up were included. Follow up data collected included: mortality, stent patency & re-intervention, with outcome analysis using the Kaplan-Meier method.

Results

97 patients were included for analysis with 254 BeGraft peripheral stents used. Median follow-up was 24 months (1-42 months). The 30 day, 1 year & 3 year patency were 100%, 99.1% & 98% respectively. 3-year freedom from stent re-intervention was 98%. The 30 day, 1 year & 3 year all-cause mortality was 2%, 10% & 24% respectively.

Conclusions

In this study, the use of the BeGraft Peripheral stent for bridging in FEVAR was safe and effective in the short to medium term. BeGraft patency and need for re-bridging stent interventions are comparable with other bridging stents.

Sex-specific differences in pre-operative Standard of Care for infra-renal AAA repair and association with peri-operative major adverse cardiovascular events and death

Anna Louise Pouncey¹, Guy Martin¹, Colin Bicknell¹, Michael Sweeting², Janet Powell¹

¹Imperial College London, London

²University of Leicester, Leicester

Background

Following elective infrarenal abdominal aortic aneurysm (IRAAA) repair, women have a higher rate of major adverse cardiovascular events and death (MACED). Disparity in pre-operative standard of care (SOC) may contribute.

Methods

Analysis using elective IRAAA repair data from the National Vascular Registry, 2013-2020. SOC defined for pre-operative assessment (multidisciplinary/anaesthetic review), waiting times, and cardiovascular risk prevention. Analyses and multivariable logistic regression conducted according to a pre-specified plan.

Results

21,810 patients (women-2380: men-19430). Women were less often repaired within SOC waiting times (51.5% vs. 59.6%, $p<0.01$), but received similar SOC pre-operative assessment (72.1% vs 72.5%, $p=ns$). Women less often had IHD (29.0% vs. 37.7%, $p<0.01$), but those with known cardiovascular co-morbidity more often received SOC risk prevention (52.1% vs. 47.3%, $p<0.01$). Overall women were less likely to receive antiplatelets (72.2% vs 75.2%, $p<0.01$) or statins (77.1% vs 80.6%, $p<0.01$).

Women were at greater risk of MACED following open (12% vs. 8.9%, $p<0.01$), and endovascular (4.9 % vs. 2.9%, $p<0.01$) repair: overall odds ratio (OR) 1.51, adjusted for age and repair type; OR 1.28 following adjustment for demographics, co-morbidities and SOC. SOC waiting time was associated with a reduction in risk (OR 0.79) for both sexes. SOC pre-operative assessment reduced MACED risk for women (OR 0.80), but not men (OR 1.09). SOC cardiovascular risk prevention did not significantly influence MACED risk.

Conclusions

Treatment within SOC waiting time is independently associated with a reduction in MACED risk for both sexes, SOC pre-operative assessment is associated with risk reduction for women only.

Outcomes following use of bovine pericardium (xenoprosthetic) grafts for aortic reconstruction of mycotic aneurysms and infected aortic grafts: A systematic review and meta-analysis

Samuel Grills¹, Nadia El-Diaz¹, Abigail Walker-Jacobs², Philip Stather²

¹University of East Anglia, Norwich

²Norfolk and Norwich University Hospital, Norwich

Background

Infected aortic grafts and mycotic aneurysms represent one of the most complex challenges faced by vascular surgeons. Treatment has progressed from extra-anatomical bypass in preference of in-situ reconstruction. Additionally, Bovine pericardium reconstruction (BPR) has increased, due to accessibility and reduced lower limb morbidity. There remains, however, limited evidence for its use. The aim is to analyse mortality, infection and post-operative complications in BPR of mycotic aortic aneurysms or infected aortic grafts.

Methods

Three databases (EMBASE, CINAHL and PUBMED) were searched for the search term “(bovine OR xenoprosthetic) AND (aneurysm)”, according to PRISMA guidelines.

Results

From nine studies, there were 133 patients: 67% graft infections; 33% mycotic aneurysms. 57% of reconstructions were in the abdominal aorta; alternative sites included femoral artery, ascending, descending and thoracic aorta. 158 pathogens were identified, including *Staphylococcus aureus* (23%), *Candida albicans* (13%) and *Escherichia coli* (13%). In 12%, no microorganisms were identified.

30-day mortality was 23% (30/133), and long-term mortality was 41% (55/133 patients). Aneurysm-specific mortality was 33%. One patient died intra-operatively. There were 148 in-hospital complications after 30-days post-operation. Common complications were acute renal failure (17%), pneumonia (14%), delirium (12%), respiratory insufficiency (11%) and renal insufficiency (7%). Eight patients (8%) reported loss of graft patency. Reinfection rate was 2% based on one study alone.

Conclusions

This meta-analysis highlights low reinfection and high graft patency using BPR, however, there remains limited long-term and comparative data regarding options for aortic reconstruction. As expected in this complex cohort, the complication rate and 30-day mortality remain high.

Acute kidney injury following endovascular intervention for peripheral artery disease

Emmanuel Katsogridakis¹, Prakash Saha², Athanasios Diamantopoulos², Nikolaos Saratzis³, Robert Davies⁴, Matt Bown¹, Athanasios Saratzis¹

¹University of Leicester, Leicester

²Guy's & St. Thomas's NHS Trust, London

³Papageorgiou General Hospital, Thessaloniki, Greece

⁴Leicester Vascular Institute, Leicester

Background

Little is known about the incidence of acute kidney injury after endovascular treatment of peripheral arterial disease. Our aim is to investigate its risk factors and estimate its incidence.

Methods

Prospective analysis of data from patients undergoing treatment of peripheral arterial disease in three centres across a five year period. The clinical endpoints were the number of patients developing AKI at 48h, and the number developing the composite Major Adverse Kidney Events (MAKE) endpoints at 30 days and 90 days (MAKE90). Multivariable regression analysis was used to assess predictors of AKI, and the association between AKI and death.

Results

Some 2041 patients were included in the analysis. AKI developed in 239 patients (11.7 per cent), with 47 (2.3 per cent) requiring dialysis within 30 days, and 18 (0.9 per cent) requiring ongoing dialysis. The MAKE30 and MAKE90 composite endpoints were reached in 358 (17.5 per cent) and 449 (22.0 per cent) patients respectively. Risk factors for AKI were age, sex, congestive heart failure, chronic limb-threatening ischaemia, emergency procedure, and pre-existing chronic kidney disease. AKI, dementia, congestive heart failure, and major amputation were risk factors for medium-term mortality.

Conclusions

AKI is a common complication after intervention for PAD and is associated with medium-term mortality.

Outcome of surgical revascularisation of acute upper limb ischemia: A single centre experience

Ayman Elsayed, Philip Stather, Ishtiaq Aziz

NNUH, Norwich

Background

The purpose of this study is to report the outcomes of surgical revascularisation in AULI in terms of technical success, clinical success, and complications.

Methods

A retrospective analysis of all 141 patients (42.6% male, median age 69 years) who presented with acute upper limb ischemia. Symptomatic patients who were deemed to require surgical revascularisation, either brachial embolectomy or more complex intervention in NNUH vascular centre from January 2010 to October 2021 were included. The baseline demographic characteristics, site of arterial occlusion, cancer status, and the potential underlying aetiology were collected along with re-intervention rates. The objective endpoints were initial technical success, re-intervention rate, local and systemic complications, functional outcome at follow-up, amputation and disease related readmission rate.

Results

CTA was the first line diagnostic imaging modality, with the brachial bifurcation as the most common location for obstruction. The initial technical success rate was 68.09% (n: 96), there were 33.33% (n: 47) postoperative major adverse events, with 12.77% (n:18) early thrombosis, and total 3.55% (n: 5) perioperative stroke and 4.96% mortality. Local complications occurred in 6.38% (n: 9), In addition 5.67% required subsequent amputation. 119 patients out of 141 (84%) have a good functional outcome with no deficit during follow-up.

Conclusions

AULI is often associated with underlying systemic and cardiac disorders. Surgical intervention is not without risk with re-thrombosis and further embolic events common. 84% of patients had a good functional outcome despite only 53% being successfully revascularised without early re-occlusion, therefore a more conservative approach may be appropriate.

A systematic review and meta-analysis of Randomized Controlled Trials comparing thermal versus non-thermal endovenous ablation in superficial venous incompetence

Noman Shahzad, Mohamed Elsherif

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

Background

Endovenous thermal ablation has replaced open varicose vein surgery where possible as first line treatment of superficial venous incompetency. Available endovenous thermal ablation modalities include Endovenous Laser Ablation (EVLA) or Endovenous Radiofrequency Ablation (RFA). Recently non-thermal endovenous ablation techniques have been used which avoid use of tumescent anaesthesia and thermal energy. These include Mechanochemical ablation and Cyanoacrylate Glue ablation.

Methods

We conducted meta-analysis of randomized controlled trials comparing effectiveness and complications of thermal versus non-thermal endovenous ablation technique for superficial venous incompetence. Google Scholar, Pubmed and Cochrane Database were searched systematically using terms to identify relevant studies to be included. Meta-Analysis of the included studies is performed using Review Manager Software Version 5.

Results

Total of 7 randomized controlled trials met the selection criteria. Occlusion of treated vein at or pto 3 months vein was reported in 3 trials whereas 4 trials reported occlusion at 1-2 year. There was no statistically significant difference in occlusion rate at 3 Months and 1 - 2 years [OR: 1.26 (0.12 – 12.69) And 2.63 (0.24 – 29.21) respectively]. Random effect mode was used due to significant heterogeneity ($I^2 > 50\%$, $p < 0.05$). There was no significant difference in quality of life as measured by Aberdeen Varicose Veins Questionnaire and Venous Clinical Severity Score.

Conclusions

There is no significant difference in occlusion rate and quality of life after thermal vs non-thermal endovenous ablation of varicose vein up to 2 years after the treatment.

Comparison of procedures pre- and post-hybrid theatre in a UK arterial vascular surgery centre

George Ninkovic-Hall, David Riding, Dana Sochorova, Simon Neequaye
Liverpool University Hospitals NHS Foundation Trust, Liverpool

Background

Hybrid theatres allow delivery of endovascular & open surgical interventions simultaneously, deploying higher quality angiography, superseding mobile 'C-arm' use. The Vascular Society of Great Britain & Ireland designated '24/7' access to a hybrid theatre as a Key Performance Indicator (KPI) for arterial centres. We compared procedures performed at our institution before & after installation of a hybrid theatre.

Methods

Our hybrid theatre became available in February 2016. We examined the procedures performed in the preceding year ('pre-hybrid'), and the subsequent five years ('hybrid'). The local operative database was interrogated and results cross-referenced with operation notes to define the procedures performed. Focus was placed on lower limb revascularisation (LLR) & abdominal aortic aneurysm (AAA) procedures.

Results

There were 226 pre-hybrid LLR, none of which included endovascular interventions. In the hybrid period (670 procedures), there were 333(49.7%) combined endovascular and open surgical interventions, 302(45.1%) were purely open, and 35(5.2%) were purely endovascular. Of the 115 pre-hybrid aortic cases, 31(27.0%) were open, with 84 (73.0%) endovascular. 75(89.3%) were EVAR/EVAS, with 4(4.8%) ChEVAR/ChEVAS and 5 (6.0%) FEVAR. In the hybrid period, of the 539 aortic procedures, there were 312(57.9%) EVAR/ EVAS, 122(22.6%) FEVAR, 51(9.5%) BEVAR, 16(3.0%) ChEVAR, 23(4.3%) TEVAR and 15(2.8%) open surgical cases.

Conclusions

The hybrid theatre at our institution has facilitated a broader range of available LLR and AAA techniques for vascular surgeons & their patients. This supports the national KPI requiring all arterial centres to have '24/7' access to hybrid theatres.

Eligibility of Common Femoral artery atherosclerotic disease for endovascular treatment – the CONFESS study

Gabriela Kaneta¹, Shehzeen Husain¹, Liam Musto², Tatiana Hamakarim³, Ahmed Elsharkawi¹, Sofia Littlejohn², Jessica Helm², Athanasios Saratzis², Hany Zayed¹

¹Guy's and St Thomas' NHS Foundation Trust, London

²Department of Cardiovascular Sciences, University of Leicester, Leicester

³King's College, London

Background

Despite advances in endovascular technologies, the proportion of CFA lesions treated with endarterectomy (CFAE) which would be amenable to endovascular treatment with modern technologies is unknown. This study aimed to describe the morphology and composition of CFA lesions treated with surgical reconstruction in two high-volume centres and report the proportion that would be amenable to endovascular treatment.

Methods

All consecutive patients presenting with symptomatic PAD from January 2014 to December 2018 who underwent CFAE were included. Extensive data relating to the anatomy and morphology of the CFA atherosclerotic lesions were collected, including in-depth analysis of the composition of the CFA plaque using 3-dimensional reconstruction based on CTA.

Results

A total of 829 CFAs in 737 patients were included (mean age 71±10 years; 526 males, 71%); 451 (62%) presented with Critical Limb Threatening Ischaemia (CLTI). Overall, 271 CFAs (33%) had a severe calcium load (>1.1 cm³) which would have required stenting; 376 (45%) target vessels had a calcium load <1.1 cm³ with a patent CFA, PFA, and proximal SFA and therefore would have been amenable to less complex endovascular treatment. Four (0.5%) target vessels were characterised by an occlusion of the CFA, EIA, SFA, and PFA, and 642 (77%) by a patent CFA, PFA, and EIA.

Conclusions

A significant proportion of patients with atherosclerotic CFA lesions who undergo surgery could potentially be candidates for endovascular treatment. A randomised trial comparing CFAE and new endovascular techniques in this clinical context is urgently required.

Inferior vena cava reconstruction: A single centre experience

Chiragh Shah, Andrew Wigham, Emma Wilton

Thames Valley Vascular Network, Oxford

Background

Inferior vena cava (IVC) stenting is carried out for symptomatic chronic IVC stenosis or occlusion, and for the treatment of malignant IVC obstruction. We aim to determine the patency of IVC stents placed for both acute-on-chronic and chronic venous occlusion.

Methods

We completed a retrospective analysis of prospectively collected data on all patients that underwent technically successful IVC stenting for treatment of symptomatic venous outflow obstruction or stenosis between February 2015 to November 2021. All patients had standard preoperative work up, including venography +/- intravascular ultrasound for chronic cases, and followed standard anticoagulation and surveillance programmes post-procedure, unless there was malignant disease.

Results

16 patients underwent IVC stenting. 7 cases (43%) presented acutely with deep vein thrombosis and chronic underlying IVC stenosis or occlusion. 5 cases (31%) were for symptomatic malignant external IVC compression. In 4 cases (25%), kissing iliac stents were placed into the IVC to treat infrarenal IVC disease. The remainder required single stents in the IVC, or were combined with double-barrelled iliac stents. Re-intervention occurred in 4 cases (25%) for in-stent thrombosis. Primary patency was 75%, and primary-assisted patency was 88%. Stenting the IVC in all cases for malignant obstruction gave symptomatic relief.

Conclusions

Stenting of the occluded / atretic IVC may require additional access from the right internal jugular vein. Stenting above and across the renal veins did not cause any additional complications in our series. Stenting of the IVC is safe, and can give significant improvement in symptoms in patients with limited alternative options for treatment.

Medium term outcomes in patients undergoing atherectomy and anti-restenotic therapy vs. bypass, for long infrainguinal in-stent occlusions

Badri Vijaynagar, Emmanuel Katsogridakis, Athanasios Saratzis
Leicester Vascular Institute, Leicester

Background

The purpose of this study was to report medium term clinical outcomes following atherectomy and anti-restenotic therapy (DAART) for in-stent occlusions below the inguinal ligament and compare these to femoro-popliteal bypass.

Methods

Data were prospectively collected for all consecutive patients who presented with chronic limb threatening ischaemia (CLTI) and had undergone previous arterial stenting (femoro-popliteal segment) between October 2018 and October 2021 in a single tertiary vascular unit. Outcomes, including amputation free survival, patency, and target lesion revascularisation (TLR) were compared between those having DAART vs. bypass. All patients were entered into a uniform surveillance programme, including 3-monthly Duplex scans.

Results

Of 26 patients, 14 (4 female; 28%) underwent DAART vs. 22 who underwent femoro-popliteal bypass (3 female; 14%). Lesions were comparable in terms of length of occlusion (19cm vs. 21cm, $p=0.09$) and number of occluded stents (2 vs. 2, $p=0.44$). Severe calcification of target lesions was common and did not differ between groups (65% vs. 63%, $p=0.19$). Over a median follow-up of 18 months (range: 4-36 months), there were no differences in amputation free survival (71% vs. 68%, $p=0.10$) or primary assisted patency (86% vs. 90%). Patients having DAART were more likely to require TLR (42% vs. 32%, $p=0.01$).

Conclusions

This series with prospective uniform follow-up including frequent imaging shows that percutaneous DAART for in-stent occlusions below the inguinal ligament has promising results, even when compared with bypass. Re-intervention rates, however, are high in both arms, especially those having DAART.

A Single Centre Early Experience of Directional Atherectomy in Managing Lower Limb Ischaemia

Tamer El-Sayed, Albagir Altahir, Matthew Thomas, James McCaslin, Craig Nesbitt

The Northern Vascular Centre, Freeman Hospital, Newcastle

Background

Directional atherectomy has increasingly become an effective and safe endovascular technique in treating patient with claudication and critical limb threatening ischaemia. This study reports a single centre early experience of using directional atherectomy.

Methods

This is a retrospective study of a prospectively collected data of patients who underwent directional atherectomy for short distance claudication or critical limb threatening ischaemia in the Northern Vascular Centre, Freeman hospital, Newcastle. 3-months primary patency, secondary patency, limb salvage/amputation, technical success, adverse events, and median lesion length were analysed.

Results

25 patients (median age 69 years [35-88]) underwent directional atherectomy between 2019 and 2021 for debilitating short distance claudication and critical limb threatening ischaemia. Patients were either unfit for major open revascularisation bypass or had hostile groin. HawkOne™ Directional Atherectomy System (Medtronic, USA) was used to treat 18 Femoral-Popliteal arteries, 3 External Iliac arteries, and 4 External Iliac and Common Femoral arteries with a median lesion length of 96.3 mm (70-109). 96% technical success with primary patency of 88%, with 100% success in resolving rest pain in CLTI and improving claudication distance to more than 200 meters. 4 patients who required re-intervention with secondary patency of 96%. 3 adverse events were observed (2 distal embolisation and one intimal dissection). 96% limb salvage rate and 4% mortality was recorded from intra-operative bleeding.

Conclusions

Directional atherectomy showed promising technical and clinical short-term outcomes in selective cases. Multi-centre randomised controlled trials are required for better understanding the long-term outcomes in managing patients with peripheral arterial disease.

Perception and acceptability of Open vs Endovascular treatment of Common Femoral Artery disease: Barriers and facilitators for Randomised Controlled Trials

Gabriela Kaneta¹, Athanasios Saratzis², Hany Zayed¹

¹Guy's and St Thomas' NHS Foundation Trust, London

²Department of Cardiovascular Sciences, University of Leicester, Leicester

Background

Endarterectomy remains the standard of care for CFA atherosclerotic disease; however, there have been advances in endovascular CFA therapies. RCTs comparing CFA treatments, though, have suffered from multiple pitfalls. This research assessed barriers and enablers of delivering high-quality RCTs in this context, from a healthcare professionals' point-of-view.

Methods

A mixed-methods qualitative study was performed, including a structured online survey and face-to-face semi-structured interviews with healthcare professionals. Survey content and interview topic guides were developed following a literature review to identify ongoing and completed RCTs. Results were analysed using thematic analysis.

Results

A total of 121 participants completed the online survey, including vascular surgeons (75, 62%) and interventional radiologists (22, 18%), mostly from the United Kingdom (92, 76%). A total of 61 participants (51%) would be willing to take part in a RCT comparing open vs. endovascular CFA revascularisation. The majority (89, 74%) believed that such an RCT is urgently needed. 15 participants were interviewed face-to-face. Five main themes emerged regarding barriers and facilitators for a high-quality RCT: factors directly limiting patient recruitment; clinicians' attitudes towards equipoise between treatments; clinicians' attitudes towards endovascular therapies; attitudes towards outcomes examined in a potential RCT; factors facilitating patient recruitment.

Conclusions

The vast majority of those surveyed believed an RCT comparing CFA treatments is necessary and would not oppose taking part in it. We have also identified important barriers and enablers, grouped in five overarching themes, which should be taken into consideration when designing and delivering such an RCT.

POSTERS & SPONSORS



Posters

Poster 1

Multiyear analysis of complex EVAR cases at a UHCW: Outcomes and performance

Alexander Sergiou

Coventry

Poster 2

Aortic Dissection management since "Think Dissection" pathway enabled at UHCW: Treatment and outcome

Alexander Sergiou

UHCW, Coventry

Poster 3

The Use of Dermal Substitutes for the Management of Diabetic Foot Ulcers in Patients with Critical Limb Ischaemia: A Systematic Review

Nina Al-Saadi¹, Djamila Rojoa², Steven Jones¹, Catherine Merriman¹

¹Royal Shrewsbury Hospital, Shrewsbury

²St Mary's Hospital, London

Poster 4

An endovascular-first approach to popliteal artery injuries resulting from traumatic knee injury.

Virginia Summerour, Alok Tiwari

UHB Heartlands Hospital, Birmingham

Poster 5

Assessment of Available Information on the World Wide Web for Patients Taking Statin Therapy

Fabio Stocco, Jing Yi Kwan, David Julian Ashbridge Scott, Marc Aaron Bailey,

Patrick Anthony Coughlin

Leeds Vascular Institute, The Leeds Teaching Hospitals NHS Foundation Trust, Leeds

Poster 6

Long-term effects of acute kidney injury in patients undergoing Endovascular treatment for peripheral arterial disease

Emmanuel Katsogridakis¹, Prakash Saha², Hany Zayed², Athanasios Diamantopoulos², Nikolaos Saratzis³, Robert Davies⁴, Matt Bown¹, Athanasios Saratzis¹

¹University of Leicester, Leicester

²Guys' and St. Thomas', London

³Papageorgiou Hospital, Thessaloniki, Greece. ⁴Leicester Vascular Institute, Leicester

Poster 7

Current evidence does not support the concept of smoking impacting durability of peripheral angioplasty and stenting: A meta-analysis

Adam Talbot, Andrew Batchelder, David Sidloff

Queens Medical Centre, Nottingham

Our Sponsors

Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional's and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott/, on Facebook at www.facebook.com/Abbott and on Twitter [@AbbottNews](https://twitter.com/AbbottNews) and [@AbbottGlobal](https://twitter.com/AbbottGlobal)

Angiodroid Srl

Angiodroid is an Italian medical device company. We give the possibility of using Carbon Dioxide as the main contrast medium for angiography procedures thanks to the use of the automatic "Angiodroid The CO2 Injector" system, validated by over 50 clinical studies and recommended by the European Guidelines.

Artivion

Artivion's recent acquisitions have empowered us to provide Cardiac and Vascular surgeons with market leading products and solutions for patients with complex Cardiac and Vascular diseases.

We have acquired a wide portfolio of Cardiac & Aortic devices and built an experienced team of respected leaders to help build brand awareness across UK & Ireland.

As our business grows rapidly, we will further support our customers by providing increased clinical support, business leadership and ground breaking ideas for future partnerships.

Bentley

Bentley's passion is the development, manufacturing and distribution of innovative implants for minimal-invasive treatments of vascular diseases. Since market launch in 2012 we rapidly expanded worldwide. Thanks to our international network of exclusive distribution partners we are represented in more than 80 countries – in some we are already market leader.

Cook Medical

A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide.

For more information, visit www.cookmedical.eu

Our Sponsors

Cydar Medical

Cydar Medical is a global cloud-based software company that provides an integrated solution for planning, navigation and review of surgical procedures using the power of augmented intelligence. Our mission is to transform the way information is provided to clinicians at every stage of the patient pathway to help them make faster, easier and safer decisions.

Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients' lives by providing innovative therapies for the interventional treatment of vascular disease. We have a therapeutic portfolio designed to treat diseases which currently have clinically relevant unmet needs. Our existing products can treat a wide spectrum of vascular disease through abdominal aortic aneurysms to lower limb peripheral vascular disease. We obtain excellent clinical outcomes through meticulous attention to product design, manufacturing, and training, all backed by industry-leading clinical evidence. With a robust pipeline of disruptive technology, our vision is to provide physicians with the best device for each patient; because when it comes to ensuring patient well-being, we are never satisfied with the status quo.

OUR PURPOSE

To revolutionize vascular care for life. Since our founding, our mission has been to save and improve the lives of patients by helping physicians transform their care.

Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimise workflows. This includes products and solutions for intensive care, cardiovascular, theatres, CSSD and life science.

Limflow

When other therapeutic options have been exhausted and a CLTI patient is facing major amputation, the minimally-invasive LimFlow System is designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot. For many, restoring perfusion in the lower limbs resolves chronic pain and prevents major amputation.

Lombard Medical

Lombard Medical is a UK-based medical device company focused solely on the minimally invasive treatment of aortic disease. In partnership with MicroPort Endovastec, we now offer the low-profile Minos™ AAA stent graft, the Hercules™ TAA stent graft and the Castor™ Branched Thoracic stent graft, in addition to our own Aorfix™, Altura™, and Fenestrated Altura™ stent grafts, creating the broadest EVAR, TEVAR, and FEVAR product portfolio for safe and innovative patient treatment.

Lombard's latest innovation is Meridian™, a fenestrated Altura stent graft which launches us into the FEVAR market, offering the only 14F fenestrated device and adding even more treatment options.

Our Sponsors

Medtronic

Bold thinking. Bolder actions. We are Medtronic.

We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world.

In everything we do, we are engineering the extraordinary.

Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in over 100 countries.

Shockwave Medical

Shockwave Medical, headquartered in Santa Clara, California is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. We aim to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through our differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which we refer to as 'Intravascular Lithotripsy.'

Terumo Aortic

At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be personalised for every patient. We are further complementing our implantable device portfolio through the development of digital technologies.

Terumo

At Terumo Interventional Systems, we constantly work to refine and perfect our products so that Vascular Surgeons and Interventional Radiologists can do more. Our exceptional tools, and education programs empower physicians with the confidence they need to perform ever-more challenging procedures and spark progress.

Our Sponsors

W.L. Gore & Associates

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world's highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of \$3.8 billion. For more information, visit gore.com

Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 50 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives.

For more information, visit goremedical.com

BSET Council 2021-2022

President:	Colin Bicknell, <i>Imperial College NHS Trust, London</i>
Secretary:	Rao Vallabhaneni, <i>Liverpool</i>
Treasurer:	James McCaslin, <i>Newcastle</i>
Education Committee Co-Chairs:	Paul Bevis, <i>Bristol</i> & Patrick Chong, <i>Frimley</i>
Research Committee Chair:	Chris Twine, <i>Bristol</i>
Meeting Committee Chair:	Bijan Modarai, <i>Guy's & St Thomas, London</i>

Council:	Dave Bosanquet, <i>Newport</i> Martin Claridge, <i>Birmingham</i> Murray Flett, <i>Dundee</i> Peter Holt, <i>St George's, London</i> Paul Moxey, <i>St George's, London</i> Simon Neequaye, <i>Liverpool</i> Athanasios Saratzis, <i>Leicester</i> Emma Wilton, <i>Oxford</i>
-----------------	--

Trainee member:	Enrico Mancuso, <i>Cambridge</i>
------------------------	----------------------------------

BSIR representatives:	Nadeem Shaidi, <i>Cambridge</i> Hunain Shiwani, <i>UCL, London</i>
------------------------------	---



BSET

British Society of
Endovascular Therapy

**The BSET Annual Meeting will be held
on the following dates:**

2023: Thursday 29th and Friday 30th June

(National Vascular Training Day Wednesday 28th June)

2024: Thursday 27th June and Friday 28th June

(National Vascular Training Day Wednesday 26th June)

**10 hours CPD has been awarded
for the meeting by the RCSEd
(RCSEd02771)**

SHOCKWAVE | IVL

SHOCKWAVE INTRAVASCULAR LITHOTRIPSY

SUB YOUR SUPERIOR STRATEGY FOR CALCIFIED PAD

EXCELLENT LONG-TERM RESULTS

IVL has demonstrated excellent patency out to two years in a severely calcified patient population.

SUPERIOR PREP

IVL'S unique MOA delivers significantly more luminal gain with lower dilation pressure and significantly lower dissections.

PRESERVED OPINIONS

IVL maintains control of the procedure by minimizing complications such as dissections, embolization, and perforations. IVL significantly reduces the need for bailout stents, preserving future treatment options.



Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions, and adverse events.

www.shockwavemedical.com

© 2022 Shockwave Medical Inc. All rights reserved. SPL- 66809 Rev. A





@BSETnews



www.bset.co.uk



office@bset.co.uk

